X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
amrubicin (227) 227
oncology (151) 151
humans (150) 150
index medicus (130) 130
chemotherapy (129) 129
male (109) 109
female (108) 108
aged (106) 106
lung neoplasms - drug therapy (105) 105
middle aged (99) 99
lung cancer (75) 75
topotecan (65) 65
cancer (64) 64
small cell lung carcinoma - drug therapy (64) 64
anthracyclines - administration & dosage (61) 61
cisplatin (56) 56
treatment outcome (56) 56
lung neoplasms - pathology (55) 55
anthracyclines - adverse effects (53) 53
antineoplastic agents - therapeutic use (53) 53
pharmacology & pharmacy (53) 53
anthracyclines - therapeutic use (52) 52
small cell lung cancer (52) 52
doxorubicin (46) 46
antineoplastic combined chemotherapy protocols - therapeutic use (45) 45
adult (44) 44
etoposide (44) 44
9-aminoanthracycline (41) 41
aged, 80 and over (39) 39
disease-free survival (39) 39
amrubicin hydrochloride (38) 38
carboplatin (37) 37
antineoplastic agents - adverse effects (36) 36
phase-ii trial (36) 36
respiratory system (36) 36
small-cell lung cancer (36) 36
care and treatment (35) 35
irinotecan (35) 35
medicine & public health (35) 35
lung neoplasms - mortality (34) 34
trial (34) 34
retrospective studies (33) 33
sm-5887 (33) 33
phase-iii trial (32) 32
research (32) 32
small cell lung carcinoma - pathology (32) 32
carcinoma, non-small-cell lung - drug therapy (30) 30
pharmacology/toxicology (27) 27
neoplasm staging (26) 26
clinical trials (24) 24
japan (24) 24
small cell lung carcinoma - mortality (23) 23
active metabolite (22) 22
amrubicinol (22) 22
anthracycline (22) 22
anthracyclines (22) 22
cancer research (22) 22
carcinoma, small cell - drug therapy (22) 22
combination (22) 22
lung cancer, small cell (22) 22
oncology, experimental (22) 22
therapy (22) 22
antineoplastic combined chemotherapy protocols - adverse effects (21) 21
camptothecin - analogs & derivatives (21) 21
drug administration schedule (21) 21
neoplasm recurrence, local - drug therapy (21) 21
relapse (21) 21
antineoplastic agents - administration & dosage (20) 20
previously untreated patients (20) 20
survival analysis (20) 20
survival rate (20) 20
analysis (19) 19
anthracycline derivative sm-5887 (19) 19
anthracyclines - pharmacology (19) 19
cell lung-cancer (19) 19
patients (19) 19
anthracyclines - pharmacokinetics (18) 18
hematology, oncology and palliative medicine (18) 18
neutropenia (18) 18
animals (17) 17
drug resistance, neoplasm (17) 17
kaplan-meier estimate (17) 17
paclitaxel (17) 17
phase-ii (17) 17
survival (17) 17
tumors (17) 17
camptothecin - administration & dosage (16) 16
carcinoma (16) 16
prognosis (16) 16
pulmonary/respiratory (16) 16
active metabolite amrubicinol (15) 15
antimitotic agents (15) 15
antineoplastic agents (15) 15
cisplatin - administration & dosage (15) 15
diseases (15) 15
drug therapy (15) 15
small cell lung carcinoma (15) 15
carboplatin - administration & dosage (14) 14
rat (14) 14
2nd-line treatment (13) 13
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American Journal of Clinical Oncology: Cancer Clinical Trials, ISSN 0277-3732, 2017, Volume 40, Issue 4, pp. 329 - 335
Journal Article
In Vivo, ISSN 0258-851X, 11/2018, Volume 32, Issue 6, pp. 1581 - 1586
Amrubicin hydrochloride is administered as second- or third-line therapy for small cell lung cancer, and is known to cause severe myelotoxicity. This study... 
relapsed | Amrubicin | phase II | refractory | small cell lung cancer | MEDICINE, RESEARCH & EXPERIMENTAL | THERAPY | TRIAL COMPARING AMRUBICIN | PACLITAXEL
Journal Article
Lung Cancer, ISSN 0169-5002, 11/2019, Volume 137, pp. 71 - 75
There are limited treatment options for patients with thymic malignancies. Here we present data supporting treatment with single agent amrubicin, a third... 
Amrubicin | Advanced stage | Thymoma | Thymic carcinoma | CARBOPLATIN | ONCOLOGY | ANTHRACYCLINE | RESPIRATORY SYSTEM | CARCINOMA | INVASIVE THYMOMA | CHEMOTHERAPY
Journal Article
Cancer, ISSN 0008-543X, 04/2019, Volume 125, Issue 7, pp. 1022 - 1026
The management of patients with relapsed/refractory small cell lung cancer is a true clinical conundrum. Using a common but challenging clinical scenario, this... 
PHASE-III TRIAL | ETOPOSIDE | MULTICENTER | EFFICACY | ONCOLOGY | TOPOTECAN | 2ND-LINE CHEMOTHERAPY | IRINOTECAN | OPEN-LABEL | AMRUBICIN | RECHALLENGE | Therapy | Refractory materials | Immune checkpoint | Small cell lung carcinoma | Lung cancer | Cancer
Journal Article
Medicine (Spain), ISSN 0304-5412, 01/2013, Volume 11, Issue 24, pp. 1441 - 1446
Small cell lung cancer is a rapid growing neoplasm with good initial response to chemotherapy treatment. However, the response is generally short-lived. In... 
Amrubicin | Chemotherapy | Concomitant
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 12/2018, Volume 13, Issue 12, pp. 1940 - 1948
Thymoma and thymic carcinoma (TC) are neoplastic diseases with reported chemosensitivity to a broad range of agents. However, because of the rarity of these... 
Thymic cancer | Thymoma | Pemetrexed | Thymic epithelial malignancies | CARBOPLATIN | THYMIDYLATE SYNTHASE | OPEN-LABEL | CHEMOTHERAPY | PREDNISONE | CISPLATIN | ONCOLOGY | VITAMIN-B-12 | RESPIRATORY SYSTEM | EPITHELIAL TUMORS | AMRUBICIN | EXPRESSION
Journal Article
British Journal of Cancer, ISSN 0007-0920, 2019, Volume 121, Issue 3, pp. 211 - 217
BACKGROUND: This exploratory single-arm phase II study evaluated the efficacy and safety of RRx-001 followed by reintroduction of platinum plus etoposide in... 
AGENT | TRIAL | APOPTOSIS | SCLC | THERAPY | ONCOLOGY | IMMUNE-RELATED RESPONSE | NITRIC-OXIDE | OPEN-LABEL | AMRUBICIN | CHEMOTHERAPY | Infusion | Chemotherapy | Motivation | Small cell lung carcinoma | Platinum | Lung cancer | Carboplatin | Etoposide | Patients | Reintroduction | Cisplatin
Journal Article
In Vivo, ISSN 0258-851X, 01/2019, Volume 33, Issue 1, pp. 163 - 166
Background: Amrubicin is usually administered on days 1-3 every 3 weeks by intravenous infusion. However, it causes severe hematological toxicity, especially... 
non-small cell lung cancer | relapsed | Amrubicin | phase II | refractory | TRIAL | MEDICINE, RESEARCH & EXPERIMENTAL | DOCETAXEL | Index Medicus
Journal Article
Cancer Science, ISSN 1347-9032, 11/2019, Volume 110, Issue 11, pp. 3573 - 3583
This study determined individual optimal amrubicin doses for Japanese patients with lung cancer after platinum‐based treatment. We carried out population... 
lung cancer | pharmacokinetics | amrubicin | amrubicinol | pharmacodynamics | Enrollments | Research & development--R&D | Lung cancer | Cell division | Single-nucleotide polymorphism | Patients | Blood | Studies | Hepatitis | Chemotherapy | Metabolites | Platinum | Response rates | Colony-stimulating factor | Pharmacokinetics | Leukocytes (granulocytic) | Neutropenia | Index Medicus | Original
Journal Article
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, ISSN 0368-2811, 10/2015, Volume 45, Issue 10, pp. 941 - 946
Most of the previous studies of amrubicin in patients with previously treated small-cell lung cancer were conducted at a dose of 40 mg/m(2). The aim of this... 
TRIAL | 9-AMINOANTHRACYCLINE | salvage chemotherapy | amrubicin | THERAPY | small-cell lung cancer | ONCOLOGY | TOPOTECAN | Phase II | CHEMOTHERAPY
Journal Article
BMC CANCER, ISSN 1471-2407, 02/2019, Volume 19, Issue 1, pp. 163 - 7
BackgroundSmall cell lung cancer (SCLC) is characterized by a high propensity for metastases and a poor prognosis irrespective of high sensitivity for initial... 
CARBOPLATIN | AUTOPSY | SAFETY | Cytotoxic chemotherapy | PHASE-III TRIAL | WEEKLY PACLITAXEL | Small cell lung cancer | CISPLATIN | ONCOLOGY | Extensive disease | PLUS ETOPOSIDE | AMRUBICIN | Interstitial pneumonia | Acute exacerbation | IDIOPATHIC PULMONARY-FIBROSIS
Journal Article
Medicine, ISSN 0025-7974, 03/2019, Volume 98, Issue 9, p. e14758
Treatment options for patients with relapsed/refractory small cell lung cancer (R/R SCLC) are limited, and the efficacy of salvage therapies for heavily... 
PHASE-III TRIAL | paclitaxel | MEDICINE, GENERAL & INTERNAL | ETOPOSIDE | CISPLATIN | BEVACIZUMAB | TOPOTECAN | nab-paclitaxel | COMPARING AMRUBICIN | small cell lung cancer | chemotherapy
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 11/2019, Volume 84, Issue 5, pp. 1059 - 1064
Amrubicin and cisplatin is one of the active regimens used to treat patients with extensive-disease (ED)-small cell lung cancer (SCLC), whereas combined... 
Amrubicin | Small cell lung cancer | Medicine & Public Health | Oncology | Cancer Research | Pharmacology/Toxicology | Radiotherapy | Cisplatin | Small cell lung carcinoma | Leukopenia | Toxicity | Lung cancer | Medical treatment | Lung diseases | Thorax | Radiation therapy | Disease control | Survival | Chemotherapy | Neutropenia
Journal Article
Oncology Research and Treatment, ISSN 2296-5270, 02/2019, Volume 42, Issue 1-2, pp. 52 - 56
Background: There are no standard cytotoxic treatments for non-small-cell lung cancer (NSCLC) patients beyond third-line therapy. The purpose of this study was... 
Research Article | Non-small-cell lung cancer | Amrubicin | Beyond third-line therapy | TRIAL | 9-AMINOANTHRACYCLINE | ONCOLOGY | PHASE-II | CHEMOTHERAPY
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.